Ebselen improves ischemia-reperfusion injury after rat lung transplantation

Jürg Hamacher, Uz Stammberger, Elvira Weber, Rudolf Lucas, Albrecht Wendel

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The heterocyclic organic compound ebselen (2-phenyl-1,2-benizsoselenazol- 3(2H)-one) is a glutathione peroxidase mimick with protective properties against oxidative injury. Ebselen also has anti-inflammatory activity, including attenuation of tumor necrosis factor release and increase of interleukin-10, as shown in vivo, in inflammatory and ischemia-reperfusion injuries, including those of the lung. This study was designed to assess its effect on severe ischemia-reperfusion injury in a model of left-sided rat lung isotransplantation. Orthotopic single left-sided lung allotransplantation (Wistar to Wistar) was performed in female rats after a total ischemic time of 18 h. In nine recipients given 500 mg/kg oral ebselen 1 h before transplantation, graft PaO2/FiO2 was improved 24 h after transplantation, as evidenced with a mean (standard deviation) PaO2 of 139 (61) mmHg vs. eight controls with 65 (33) mmHg (p = 0.009). Bronchoalveolar PMN count was reduced to approximately 50% in the ebselen group compared with controls, whereas no difference in the tumor necrosis factor content was found. We conclude that the improvement of lung function in ebselen-treated transplanted rats is mainly the result of the anti-inflammatory activity of the drug during reperfusion.

Original languageEnglish (US)
Pages (from-to)98-103
Number of pages6
JournalLung
Volume187
Issue number2
DOIs
StatePublished - Apr 1 2009

Fingerprint

Lung Transplantation
Reperfusion Injury
Lung
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Transplantation
Heterocyclic Compounds
Glutathione Peroxidase
Interleukin-10
Reperfusion
ebselen
Transplants
Wounds and Injuries
Pharmaceutical Preparations

Keywords

  • Anti-inflammatory agents
  • Ebselen
  • Lung transplantation
  • Reperfusion injury

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Ebselen improves ischemia-reperfusion injury after rat lung transplantation. / Hamacher, Jürg; Stammberger, Uz; Weber, Elvira; Lucas, Rudolf; Wendel, Albrecht.

In: Lung, Vol. 187, No. 2, 01.04.2009, p. 98-103.

Research output: Contribution to journalArticle

Hamacher, J, Stammberger, U, Weber, E, Lucas, R & Wendel, A 2009, 'Ebselen improves ischemia-reperfusion injury after rat lung transplantation', Lung, vol. 187, no. 2, pp. 98-103. https://doi.org/10.1007/s00408-009-9134-x
Hamacher, Jürg ; Stammberger, Uz ; Weber, Elvira ; Lucas, Rudolf ; Wendel, Albrecht. / Ebselen improves ischemia-reperfusion injury after rat lung transplantation. In: Lung. 2009 ; Vol. 187, No. 2. pp. 98-103.
@article{e550ee46997e4d3195bef55f928f7270,
title = "Ebselen improves ischemia-reperfusion injury after rat lung transplantation",
abstract = "The heterocyclic organic compound ebselen (2-phenyl-1,2-benizsoselenazol- 3(2H)-one) is a glutathione peroxidase mimick with protective properties against oxidative injury. Ebselen also has anti-inflammatory activity, including attenuation of tumor necrosis factor release and increase of interleukin-10, as shown in vivo, in inflammatory and ischemia-reperfusion injuries, including those of the lung. This study was designed to assess its effect on severe ischemia-reperfusion injury in a model of left-sided rat lung isotransplantation. Orthotopic single left-sided lung allotransplantation (Wistar to Wistar) was performed in female rats after a total ischemic time of 18 h. In nine recipients given 500 mg/kg oral ebselen 1 h before transplantation, graft PaO2/FiO2 was improved 24 h after transplantation, as evidenced with a mean (standard deviation) PaO2 of 139 (61) mmHg vs. eight controls with 65 (33) mmHg (p = 0.009). Bronchoalveolar PMN count was reduced to approximately 50{\%} in the ebselen group compared with controls, whereas no difference in the tumor necrosis factor content was found. We conclude that the improvement of lung function in ebselen-treated transplanted rats is mainly the result of the anti-inflammatory activity of the drug during reperfusion.",
keywords = "Anti-inflammatory agents, Ebselen, Lung transplantation, Reperfusion injury",
author = "J{\"u}rg Hamacher and Uz Stammberger and Elvira Weber and Rudolf Lucas and Albrecht Wendel",
year = "2009",
month = "4",
day = "1",
doi = "10.1007/s00408-009-9134-x",
language = "English (US)",
volume = "187",
pages = "98--103",
journal = "Lung",
issn = "0341-2040",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Ebselen improves ischemia-reperfusion injury after rat lung transplantation

AU - Hamacher, Jürg

AU - Stammberger, Uz

AU - Weber, Elvira

AU - Lucas, Rudolf

AU - Wendel, Albrecht

PY - 2009/4/1

Y1 - 2009/4/1

N2 - The heterocyclic organic compound ebselen (2-phenyl-1,2-benizsoselenazol- 3(2H)-one) is a glutathione peroxidase mimick with protective properties against oxidative injury. Ebselen also has anti-inflammatory activity, including attenuation of tumor necrosis factor release and increase of interleukin-10, as shown in vivo, in inflammatory and ischemia-reperfusion injuries, including those of the lung. This study was designed to assess its effect on severe ischemia-reperfusion injury in a model of left-sided rat lung isotransplantation. Orthotopic single left-sided lung allotransplantation (Wistar to Wistar) was performed in female rats after a total ischemic time of 18 h. In nine recipients given 500 mg/kg oral ebselen 1 h before transplantation, graft PaO2/FiO2 was improved 24 h after transplantation, as evidenced with a mean (standard deviation) PaO2 of 139 (61) mmHg vs. eight controls with 65 (33) mmHg (p = 0.009). Bronchoalveolar PMN count was reduced to approximately 50% in the ebselen group compared with controls, whereas no difference in the tumor necrosis factor content was found. We conclude that the improvement of lung function in ebselen-treated transplanted rats is mainly the result of the anti-inflammatory activity of the drug during reperfusion.

AB - The heterocyclic organic compound ebselen (2-phenyl-1,2-benizsoselenazol- 3(2H)-one) is a glutathione peroxidase mimick with protective properties against oxidative injury. Ebselen also has anti-inflammatory activity, including attenuation of tumor necrosis factor release and increase of interleukin-10, as shown in vivo, in inflammatory and ischemia-reperfusion injuries, including those of the lung. This study was designed to assess its effect on severe ischemia-reperfusion injury in a model of left-sided rat lung isotransplantation. Orthotopic single left-sided lung allotransplantation (Wistar to Wistar) was performed in female rats after a total ischemic time of 18 h. In nine recipients given 500 mg/kg oral ebselen 1 h before transplantation, graft PaO2/FiO2 was improved 24 h after transplantation, as evidenced with a mean (standard deviation) PaO2 of 139 (61) mmHg vs. eight controls with 65 (33) mmHg (p = 0.009). Bronchoalveolar PMN count was reduced to approximately 50% in the ebselen group compared with controls, whereas no difference in the tumor necrosis factor content was found. We conclude that the improvement of lung function in ebselen-treated transplanted rats is mainly the result of the anti-inflammatory activity of the drug during reperfusion.

KW - Anti-inflammatory agents

KW - Ebselen

KW - Lung transplantation

KW - Reperfusion injury

UR - http://www.scopus.com/inward/record.url?scp=67649130167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649130167&partnerID=8YFLogxK

U2 - 10.1007/s00408-009-9134-x

DO - 10.1007/s00408-009-9134-x

M3 - Article

C2 - 19198941

AN - SCOPUS:67649130167

VL - 187

SP - 98

EP - 103

JO - Lung

JF - Lung

SN - 0341-2040

IS - 2

ER -